CompletedNot Applicable

H-IVIG Treatment for Severe H1N1 2009

Hong Kong34 participantsStarted 2010-01

Plain-language summary

Treatment with hyperimmune intravenous immunoglobulin (H-IVIG), derived from convalescent plasma from patients recovered from H1N1 2009 influenza A infection, for patients with severe H1N1 2009 infection will decrease mortality, reduce viral load, and shorten the length of stay in ICU and hospital.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Laboratory criteria: at least one RT-PCR positive for H1N1 2009 from one of the clinical specimens (NPA, ETA, blood, urine or stool).
✓. Clinical criteria: patients admitted to ICU with severe community acquired pneumonia as defined by a CURB-65 score of 3 or more

What they're measuring

Mortality

Timeframe: From date of randomization until the date of death from any cause during hospitalization, assessed up to 6 months

Trial details

NCT IDNCT01617317

SponsorThe University of Hong Kong

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-11

View on ClinicalTrials.gov More Novel 2009 Influenza A (H1N1) Infection trials